
    
      The risks of CVD are not confined to a subset of established "hypertensive" or "diabetic"
      population, but also increase among those with suboptimal blood pressure and glycemic level,
      namely "pre-hypertensive" or "pre-diabetic" population. Evidence on the effectiveness of drug
      interventions to lower CVD events in pre-clinical stage population has been scant.
    
  